The expert commission of the US medical regulator FDA recommended vaccination against coronavirus in children aged 5-11 years.
Seventeen of the eighteen members of the FDA commission voted that the benefits of Pfizer vaccine vaccination outweigh the risks; one abstained.
“Based on the totality of available scientific data, can we assume that the benefits of vaccination from Pfizer-BioNTech COVID-19, when used in two doses (10 milligrams each with an interval of three weeks), outweigh the risks of use among children aged 5-11 years?” the question put up for discussion sounded.
Experts from another regulator, the Center for Disease Control and Prevention (CDC), are scheduled to discuss the same issue on November 2-3.
If approved, the vaccine will be available to 28 million children. The White House has announced that it is already working to start vaccination a few days after the CDC’s approval.
